|
|
 |
|
Viewing report
|
|
|
|
Coagulation Factors 2011 - Who does meet the market needs? A Pipeline Assessment, Market Survey and Corporate Benchmark Analysis
La Merie Publishing, Oct 2011, Pages: 162
Global sales of the five major recombinant products of coagulation factors VIII, IX and VIIa in 2010 were US$ 6.2 bln (with $ conversion rate October 19, 2010). The first Marketing Authorization Application for a novel recombinant coagulation factor has been submitted in the European Union and further novel wild-type and long-acting recombinant coagulation factors VIII, IX and VII are in advanced clinical stages with potential regulatory approvals within the next 2 to 4 years. Given the progress of the pipeline, a concentration process of players has started. First clinical data are available and will guide further definition of R&D in this field.
The report “Coagulation Factors 2011 – who does meet the market needs? A Pipeline Assessment, Market Survey and Corporate Benchmark Analysis” provides a description, evaluation and assessment of the recombinant coagulation factor R&D pipelines as of October 2011. The authors analyze and assess the target pipeline for each of the coagulation factors for haemophilia and work out the target profiles of development projects. A market research study was conducted to challenge industry's target profiles and evaluate the sensitivity for pricing.
The report is built upon primary and secondary search for information and use of a proprietary database and news portal. A market survey was conducted among haematologists from haemophilia care centers. In house analysts with experience in biopharmaceutical R&D and business development authored the report and analysed and assessed the findings.
Scope of the report:
- R&D pipeline overview
- profiles of most promising coagulation factors in the pipeline
- pipeline analysis for each coagulation factor
- evaluation and assessment of protein engineering and drug delivery technologies
- overview and analysis of marketed coagulation factors;
- market research study with haematologists from haemophilia care centers
- corporate product portfolios and R&D pipelines;
- benchmark of competitors regarding achievement of product target profiles
Benefits from the report:
- Understand your position in a highly competitive environment
- Learn what haematologists think about your product target profiles
- Understand the market needs
- Know pricing sensitivities for your haemophilia products
- Learn from your competitors
- Challenge your strategy with a view from outside the organization
|
|
|
|
